A suburban Philadelphia animal health company has entered into an exclusive license agreement with the Wistar Institute to further advance a canine melanoma vaccine and other vaccines for cancer and infectious diseases in animals.

Financial terms of the deal between Man’s Best Friend Therapeutics (MBFT) of Ambler, Pa., and Wistar, a Philadelphia nonprofit research institute, were not disclosed. The agreement includes an expansion of their existing sponsored research collaboration, established last year, focused on evaluating the safety and effectiveness of immunotherapeutic vaccines for companion and domestic animals based on technology created at Wistar.

The partnership was created to leverage Wistar’s vaccine research expertise with MBFT’s capabilities in developing animal health products.

The vaccine candidate for canine melanoma, MBFT-201 is based on a platform developed and patented by Dr. Hildegund C.J. Ertl, a vaccine research professor and member of Wistar’s Vaccine & Immunotherapy Center, who devised a way to combine the advantages of a vaccine technology with the power of immune checkpoint blockade therapy to go after tumor cells.

Read the full article here.